User profiles for P. Wallemacq

Pierre Wallemacq

Cliniques universitaires St Luc, Université catholique de Louvain
Verified email at uclouvain.be
Cited by 12858

[PDF][PDF] Annual disaster statistical review 2016

D Guha-Sapir, P Hoyois, P Wallemacq… - The numbers and …, 2017 - dial.uclouvain.be
Objective The Centre promotes research and provides an evidence base for the international
community, both on the burden of disease and health issues related to disasters and …

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference

P Wallemacq, VW Armstrong, M Brunet… - Therapeutic drug …, 2009 - journals.lww.com
… minimum trough TAC trough concentrations (P = 0.021). A … effects (P = 0.001) but not with
organ rejection (P = 0.323). … increasing incidence of adverse effects (P = 0.046) using logistical …

Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report

…, M Shipkova, A Vinks, P Wallemacq… - Therapeutic drug …, 2019 - journals.lww.com
Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant …

…, D Lison, JP Squifflet, P Wallemacq - Pharmacogenetics …, 2004 - journals.lww.com
… substrates for P-glycoprotein (P-gp), the product of the multidrug resistance (MDR1) gene [
18 ]. P-… The gastrointestinal absorption of P-gp substrates is inversely proportional to the P-gp …

[HTML][HTML] Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

…, X Wittebole, D De Backer, B Layeux, P Wallemacq… - Critical care, 2010 - Springer
… As there is a large variance in MIC values for different bacteria, we considered the MICs
for problematic pathogens, such as P. aeruginosa, commonly isolated in ICU patients, as the …

Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.

M Buysschaert, AS Dramais, PE Wallemacq… - Diabetes …, 2000 - Am Diabetes Assoc
OBJECTIVE: The aim of this study was to determine the distribution of plasma total
homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy …

[HTML][HTML] Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

…, B Layeux, D De Backer, X Wittebole, P Wallemacq… - Critical care, 2010 - Springer
… Simulation with doses calculated by using the IBW showed that only 35 (47%) patients
would have reached a peak >64 μg/ml (P < 0.01 compared with a regimen established by using …

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

V Haufroid, P Wallemacq… - American journal of …, 2006 - Wiley Online Library
p values less than 0.05 were considered statistically significant. All values are expressed
as median and range unless otherwise stated. Multiple regression analysis models were used …

Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology

…, NT Vethe, AA Vinks, P Wallemacq… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil

…, R Schepers, JP Squifflet, P Wallemacq - Clinical …, 2001 - academic.oup.com
… be made (P <… P values are those of P >|t| (ie, the probability of obtaining a greater absolute
t value by chance alone if there is no difference between pairs or sample means). This is the P